ALCHEMIA REPORTS NET LOSS OF $15.8M

ALCHEMIA REPORTS NET LOSS OF $15.8M

BRISBANE biotech company Alchemia (ASX:ACL) has reported a net loss of $15.8 million for the first half of the 2015 financial year, compared to $5.5 million for the six months ending 31 December 2013.

A contributing factor of this result was the failure of its recent cancer drug trial.

The pivotal phase three clinical trial of HA-Irinotecan in metastatic colorectal cancer failed to reach its primary endpoint in significant improvement in progression free survival and did not meet its secondary endpoint of an improvement in overall-survival.

This led to shares dropping by 83 per cent from 51.5 cents to 10.5 cents, in November 2014. 

Since the announcement of the above results, ACL has undergone a strategic review of all its assets and operations.

In addition, ACL has recorded profit share income arising from sales of fondaparinux - a collaboration agreement with Dr Reddy's Laboratories - of $2.8 million for the period and had net assets of $11.6 million.

In addition, operating expenditure of $24.9 million increased by $14.2 million over the corresponding period.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Four ways businesses can use artificial intelligence to triumph in 2022
Partner Content
The last two years have delivered major disruption to the technology industry and broad...
PROS
Advertisement

Related Stories

Brisbane Top Companies revealed

Brisbane Top Companies revealed

Brisbane’s top companies have been a hotbed of growth in 2021...

Brisbane Top Companies 1-10

Brisbane Top Companies 1-10

The top 10 Brisbane listed companies list has seldom changed as muc...

Brisbane Top Companies 11-20

Brisbane Top Companies 11-20

The 11-20 section of the Brisbane Top Companies list is founder-hea...

Brisbane Top Companies 21-30

Brisbane Top Companies 21-30

A battery tech spin-off and an initial public offering (IPO) have c...